» Articles » PMID: 28691014

Drug Target Protein-Protein Interaction Networks: A Systematic Perspective

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2017 Jul 11
PMID 28691014
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

The identification and validation of drug targets are crucial in biomedical research and many studies have been conducted on analyzing drug target features for getting a better understanding on principles of their mechanisms. But most of them are based on either strong biological hypotheses or the chemical and physical properties of those targets separately. In this paper, we investigated three main ways to understand the functional biomolecules based on the topological features of drug targets. There are no significant differences between targets and common proteins in the protein-protein interactions network, indicating the drug targets are neither hub proteins which are dominant nor the bridge proteins. According to some special topological structures of the drug targets, there are significant differences between known targets and other proteins. Furthermore, the drug targets mainly belong to three typical communities based on their modularity. These topological features are helpful to understand how the drug targets work in the PPI network. Particularly, it is an alternative way to predict potential targets or extract nontargets to test a new drug target efficiently and economically. By this way, a drug target's homologue set containing 102 potential target proteins is predicted in the paper.

Citing Articles

The Atlas of Protein-Protein Interactions in Cancer (APPIC)-a webtool to visualize and analyze cancer subtypes.

Ahn B, Chou C, Chou C, Chen J, Zug A, Baykara Y NAR Cancer. 2025; 7(1):zcae047.

PMID: 39822275 PMC: 11734624. DOI: 10.1093/narcan/zcae047.


Computer-Aided Identification and Design of Ligands for Multi-Targeting Inhibition of a Molecular Acute Myeloid Leukemia Network.

Asfa S, Arshinchi Bonab R, Onder O, Uca Apaydin M, Doseme H, Kucuk C Cancers (Basel). 2024; 16(21).

PMID: 39518047 PMC: 11544916. DOI: 10.3390/cancers16213607.


approaches supporting drug repurposing for Leishmaniasis: a scoping review.

Scheiffer G, Domingues K, Gorski D, Cobre A, Lazo R, Borba H EXCLI J. 2024; 23:1117-1169.

PMID: 39421030 PMC: 11484518. DOI: 10.17179/excli2024-7552.


Drug-target interaction prediction with collaborative contrastive learning and adaptive self-paced sampling strategy.

Tian Z, Yu Y, Ni F, Zou Q BMC Biol. 2024; 22(1):216.

PMID: 39334132 PMC: 11437672. DOI: 10.1186/s12915-024-02012-x.


Molecular docking and antimicrobial activities of photoexcited inhibitors in antimicrobial photodynamic therapy against Enterococcus faecalis biofilms in endodontic infections.

Pourhajibagher M, Javanmard Z, Bahador A AMB Express. 2024; 14(1):94.

PMID: 39215887 PMC: 11365891. DOI: 10.1186/s13568-024-01751-y.


References
1.
Yates C, Sternberg M . Proteins and domains vary in their tolerance of non-synonymous single nucleotide polymorphisms (nsSNPs). J Mol Biol. 2013; 425(8):1274-86. DOI: 10.1016/j.jmb.2013.01.026. View

2.
Sams-Dodd F . Target-based drug discovery: is something wrong?. Drug Discov Today. 2005; 10(2):139-47. DOI: 10.1016/S1359-6446(04)03316-1. View

3.
Bakheet T, Doig A . Properties and identification of human protein drug targets. Bioinformatics. 2009; 25(4):451-7. DOI: 10.1093/bioinformatics/btp002. View

4.
KROGH A, Larsson B, von Heijne G, Sonnhammer E . Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol. 2001; 305(3):567-80. DOI: 10.1006/jmbi.2000.4315. View

5.
Nacher J, Schwartz J . A global view of drug-therapy interactions. BMC Pharmacol. 2008; 8:5. PMC: 2294115. DOI: 10.1186/1471-2210-8-5. View